Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
α-Syn H21 in Multiple System Atrophy
NCT07774585Phase 1Not yet recruiting
- Sponsor
- Ruijin Hospital
- Start
- Sep 2026
- Primary completion
- Dec 2026
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of α-Syn H21 monoclonal antibody in multiple system atrophy (MSA), sponsored by Ruijin Hospital. Primary endpoints: Incidence of treatment-emergent adverse events at 12 weeks, Unified Multiple System Atrophy Rating Scale Total Score at 12 weeks and 1 more. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
α-Syn H21 monoclonal antibody
03
Conditions
multiple system atrophy (MSA)
Beyond the preview
Go deeper on NCT07774585.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07774585.